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Abstract  
Despite the enormous victory that has been recorded in decreasing significantly HIV-TB related mortality and morbidity in Sub-Saharan Africa, 
enormous challenges continue to obstruct proper and enviable control of these conditions. These range from prioritization, ethics, funding, drug 
resistance and research gaps. Resistance to these diseases could constitute key treatment and prevention challenges to health care systems and 
the international community if not handled appropriately and promptly. This paper presents key shortcomings of the current funding, management 
and research policies and highlights possible action areas to remedy this situation. 
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Highly Active Anti –Retroviral Therapy (HAART) and Anti-
Mycobacterium Tuberculosis (TB) therapies today have remarkably 
reduced HIV-TB associated morbidity and mortality. These 
successes however might be compromised or short lived with the 
growing resistant strains to available drugs. Not only health systems 
risk becoming unable to afford for second and third line therapies 
for the ever-growing affected patients with such strains, new 
patients risk getting infected with resistant strains [1- 4]. 
Remarkable successes have been made to increase availability of 
screening tests for both conditions and drugs have been universally 
made available and affordable. Empirical research findings are 
disappointing from an ethical point of view with numerous incidence 
of coercion, testing without obtaining consent from parties, 
screened persons not aware they have the opportunity to turn down 
the test if they want and many clients retrospectively saying their 
choices were purely influenced by health care staff [5,6]. Directive 
counseling and conditioning clients to get screened as a 
precondition to receive health care has been reported [5]. This is 
not only unethical, but could be counterproductive when these 
clients come to know they had the right to turn down these tests. 
Consequences could range from lack of trust in the health care 
system [7], that could affect not only HIV-TB care, but also other 
medical conditions. Participation in future research, a key corner 
stone to inform health policy could also be seriously compromised.  
  
However, getting a diagnosis is no guarantee of an appropriate 
behavioral change later or being compliant to the prescribed 
therapy. Resistance to HAART and Anti-TB drugs is becoming a 
serious public health threat for health systems to sustain [1 – 4]. 
Second line and third line therapies are relatively expensive, scarce 
and at times not very effective is envisaged. As the scientific 
community enviably awaits complete curative therapies or vaccines 
for these conditions, it might be more reasonable to preserve the 
effectiveness of existent proven effective therapies. Making HIV 
testing available without taking into consideration the conditions 
under which this test is done is a key shortcoming of current 
practice. The quality of counseling and psychosocial support remain 
key in the management of such stigmatizing conditions like HIV and 
TB. The number of clinical psychologists, social workers and trained 
counselors in the health sector remains almost nonexistent in most 
health care settings in Sub-Saharan Africa. Though the level of HIV 
associated stigma has reduced remarkably in most countries, there 
is still a long way to go in most developing countries. Improving on 
the quality of pre and post - test counseling , coupled with 
psychosocial support could be the only gateways to safeguard 
compliance to prescribed biomedical regimes. Research funding in 
understanding non – compliance to effective treatment regimens 
has been grossly insufficient.  
  
As the scientific community enviably awaits an HIV and TB vaccine 
or cure, safe - guarding effectiveness of available proven treatment 
options could be more realistic and cost saving. We argue that the 
emphasis on training and employment of clinical psychologists, 
counselors and social workers has been insufficient and neglected in 
most Sub-Saharan African Settings. HIV and TB still remain 
stigmatizing conditions in these settings and such actors remain 
unavoidable in case improved compliance is envisaged. Increasing 
research funding in understanding non-compliance to current 
biomedical regimes from a social, culture specific and sensitive 
perspective are compelling. Without disregarding the utmost 
importance of HIV-TB cure and vaccine research, we argue that it 
might be too early to underrate preserving effectiveness of current 
proven therapies. The danger could be an epidemic of highly 
resistant HIV-TB strains that could surpass the capacities of health 
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